N/A
N=1,713
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes
Type2 Diabetes
Bottom Line
View on ClinicalTrials.gov: NCT03362112 ↗Enrolled (actual)
1,713
Serious AEs
—
Results posted
Apr 2022
Primary outcome: Primary: Lipoprotein-associated Phospholipase A2 — 238.4 ng/ml
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
- Primary completion
- Aug 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lipoprotein-associated Phospholipase A2 |
238.4 | — |
| SECONDARY HbA1c |
9.1 | — |
| SECONDARY LDL-c |
2.5 | — |
| SECONDARY Diabetic Complication |
— | — |
| SECONDARY C Peptide |
— | — |
Summary
Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).
Eligibility Criteria
Inclusion Criteria
- Patients with T2D and the diagnostic criteria of T2D is according to the World Health Organization in 1999.
Exclusion Criteria
- Patients use systemic steroidal anti-inflammatory drugs.
- Patients are pregnant.
- Patients with an acute infection.
Data sourced from ClinicalTrials.gov (NCT03362112). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.